About Exagen
Exagen is a company based in Vista (United States) founded in 2002. It operates as a HealthTech and Professional Services. Exagen has raised $110.23 million across 36 funding rounds from investors including Sun Mountain Capital, HIG BioHealth Partners and Innovatus Capital Partners. The company has 209 employees as of December 31, 2024. Exagen offers products and services including AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, and AVISE APS. Exagen operates in a competitive market with competitors including HYCOR BioMedical, Kypha, Lophius Biosciences, SmartHealth and TBG Diagnostics, among others.
- Headquarter Vista, United States
- Employees 209 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exagen Inc.
-
Annual Revenue
$55.64 M (USD)5.89as on Dec 31, 2024
-
Net Profit
-$15.12 M (USD)36.19as on Dec 31, 2024
-
EBITDA
-$11.91 M (USD)42.37as on Dec 31, 2024
-
Total Equity Funding
$110.23 M (USD)
in 36 rounds
-
Latest Funding Round
$22.6 M (USD), Series C
Jul 16, 2019
-
Investors
Sun Mountain Capital
& 7 more
-
Employee Count
209
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Exagen
Exagen is a publicly listed company on the NASDAQ with ticker symbol XGN in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Exagen
Exagen offers a comprehensive portfolio of products and services, including AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, and AVISE APS.
Testing for SLE and connective tissue diseases is provided.
Diagnostic testing for systemic lupus erythematosus is offered.
Monitoring of systemic lupus erythematosus disease is conducted.
Prognostic testing for systemic lupus erythematosus is available.
Testing for antiphospholipid syndrome is provided to patients.
People of Exagen
Unlock access to complete
Unlock access to complete
Funding Insights of Exagen
Exagen has successfully raised a total of $110.23M across 36 strategic funding rounds. The most recent funding activity was a Series C round of $22.6 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Exagen
Exagen has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Sun Mountain Capital, HIG BioHealth Partners and Innovatus Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified debt funding is provided for growth capital opportunities.
|
Locked | Locked | Locked | |
|
Private equity fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Exagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exagen
Investment portfolio details for Exagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Exagen
Detailed financials for Exagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exagen Comparisons
Peer comparison for Exagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exagen
Exagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Kypha, Lophius Biosciences, SmartHealth and TBG Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
|
| Locked | Locked | Locked |
Diagnostic biomarker tests for inflammation and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
T-cell-based diagnostics for infectious and immune diseases are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostics for vascular, metabolic, and oncological diseases are developed.
|
|
| Locked | Locked | Locked |
Molecular diagnostics kits, instruments, and software are developed and manufactured.
|
Detailed competitors of Exagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exagen
Complete news archive for Exagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exagen
Exagen was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Exagen is headquartered in Vista, United States. It is registered at Vista, California, United States.
Exagen is a funded company, having raised a total of $110.23M across 36 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Exagen is 209.
Annual revenue of Exagen is $55.64M as on Dec 31, 2024.
Exagen Inc. is engaged in providing advanced diagnostic, prognostic, and monitoring testing for autoimmune conditions. The company operates in the healthcare sector, specializing in rheumatology and lupus biomarkers. Solutions are developed to aid physicians in accurate and timely diagnosis and management of autoimmune diseases. Testing services like AVISE CTD, AVISE Lupus, and others are offered to improve patient outcomes through next-generation insights. Partnerships with biopharma and clinical trial support are also maintained to enhance research and development efforts.
Exagen's top competitors include SmartHealth, HYCOR BioMedical and Lophius Biosciences.
Exagen offers AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, and AVISE APS.
Yes, Exagen is publicly traded on NASDAQ under the ticker symbol XGN.
Exagen has 8 investors. Key investors include Sun Mountain Capital, HIG BioHealth Partners, Innovatus Capital Partners, Cottonwood Technology Fund, and CRG.
The ticker symbol of Exagen is XGN on NASDAQ.